Safety of Diamyd® in Patients With LADA (Latent Autoimmune Diabetes in Adult)
Status:
Completed
Trial end date:
2008-04-01
Target enrollment:
Participant gender:
Summary
This is a study to investigate the safety of 20ug Diamyd® (rhGAD65 formulated in
Alhydrogel®), administered subcutaneously four weeks apart in patients with Latent Autoimmune
Diabetes in Adult (LADA).